Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: Results from the SEARCH database

European Urology

Volumn 65, Issue 3, 2014, Pages 620-627

  Keto, Christopher J ^a,b   Aronson, William J ^c,d   Terris, Martha K ^d,e   Presti, Joseph C ^f,g   Kane, Christopher J ^h   Amling, Christopher L ⁱ   Freedland, Stephen J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^g VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Androgen deprivation therapy; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN-DEPRIVATION THERAPY; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN;

AGED; ANDROGEN ANTAGONISTS; ANILIDES; DATABASES, FACTUAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NITRILES; ORCHIECTOMY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84895061392     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.11.052     Document Type: Article

References (21)

1. M.E. Stokes, L. Black, A. Benedict, C.G. Roehrborn, and P. Albertsen Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data Prostate Cancer Prostatic Dis 13 2010 278 284
2. M.M. Center, A. Jemal, and J. Lortet-Tieulent et al. International variation in prostate cancer incidence and mortality rates Eur Urol 61 2012 1079 1092
3. A. Heidenreich, J. Bellmunt, and M. Bolla et al. EAU guidelines on prostate cancer, I: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
4. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597 (Pubitemid 29211767)
5. N. Sharifi, J.L. Gulley, and W.L. Dahut Androgen deprivation therapy for prostate cancer JAMA 294 2005 238 244 (Pubitemid 41043794)
6. S.J. Freedland, J. Eastham, and N. Shore Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer Prostate Cancer Prostatic Dis 12 2009 333 338
7. V. Pagliarulo, S. Bracarda, and M.A. Eisenberger et al. Contemporary role of androgen deprivation therapy for prostate cancer Eur Urol 61 2012 11 25
8. N. Mottet, J. Bellmunt, and M. Bolla et al. EAU guidelines on prostate cancer, II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 59 2011 572 583
9. A.J. Stewart, H.I. Scher, and M.H. Chen et al. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure J Clin Oncol 23 2005 6556 6560 (Pubitemid 46190248)
10. M. Hussain, C.M. Tangen, and C. Higano et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984 3990 (Pubitemid 46630748)
11. J.I. Miller, F.R. Ahmann, G.W. Drach, S.S. Emerson, and M.R. Bottaccini The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer J Urol 147 1992 956 961
12. C. Kwak, S.J. Jeong, M.S. Park, E. Lee, and S.E. Lee Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer J Urol 168 2002 995 1000
13. L.L. Banez, R.M. Loftis, and S.J. Freedland et al. The influence of hepatic function on prostate cancer outcomes after radical prostatectomy Prostate Cancer Prostatic Dis 13 2010 173 177
14. S.L. Chang, S.J. Freedland, and M.K. Terris et al. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database Urology 75 2010 439 444
15. H.I. Scher, S. Halabi, and I. Tannock et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
16. E.A. Benaim, C.M. Pace, P.M. Lam, and C.G. Roehrborn Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer Urology 59 2002 73 78 (Pubitemid 34059310)
17. B.M. Alexander, M.H. Chen, P. Carroll, and A.V. D'Amico Prostate-specific antigen level at initiation of hormonal therapy after prostate-specific antigen failure following prostatectomy or radiotherapy and therapeutic response Urology 70 2007 320 323 (Pubitemid 47362261)
18. M.R. Smith Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer Clin Cancer Res 13 2007 241 245 (Pubitemid 46121875)
19. J. Morote, A. Orsola, and J. Planas et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy J Urol 178 2007 1290 1295 (Pubitemid 47368393)
20. M. Perachino, V. Cavalli, and F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 105 2010 648 651
21. B. Tombal, K. Miller, and L. Boccon-Gibod et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics Eur Urol 57 2010 836 842